TCM
ESPR

Traynor Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Traynor Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.5K Hold
14,386
– – ﹤0.01% 353
2026
Q1 		$37.8K Hold
14,386
– – ﹤0.01% 327
2025
Q4 		$53.2K Buy
+14,386
New +$46.5K ﹤0.01% 342

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Traynor Capital Management's ESPR Position: Q2 2026 in Review

Traynor Capital Management held its Esperion Therapeutics (ESPR) position steady in Q2 2026 at 14,386 shares worth $45.5K. The position accounts for ﹤0.01% of the portfolio, ranked #353.

Traynor Capital Management first reported a position in ESPR in Q4 2025 and has held it in 3 quarters since. The position peaked at $53.2K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Traynor Capital Management held 14,386 shares of Esperion Therapeutics worth $45.5K as of Q2 2026.
  • Traynor Capital Management left its Esperion Therapeutics share count unchanged in Q2 2026.
  • Esperion Therapeutics made up ﹤0.01% of Traynor Capital Management's portfolio in Q2 2026, its #353 holding.
  • Traynor Capital Management first reported a position in Esperion Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Traynor Capital Management's Esperion Therapeutics position peaked at $53.2K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Traynor Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.